Relapsing-remitting patterns of many autoimmune diseases such as multiple sclerosis (MS) are perpetuated by a recurring circuit of adaptive immune cells that amplify in secondary lympho id organs (SLOs) and traffic to compartments where antigen is abundant to elicit damage. Some of the most effective immunotherapies impede the migration of immune cells through this circuit, however, broadly suppressing immune cell migration can introduce life-threatening risks for patients. We developed antigen-specific immune decoys (ASIDs) to mimic tissues targeted in autoimmunity and selectively intercept autoimmune cells to preserve host tissue. Using Experimental Autoimmune Encephalomyelitis (EAE) as a model, we conjugated autoantige n PLP139-151 to a microporous collagen scaffold. By subcutaneously implanting ASIDs after induction but prior to the onset of symptoms, mice were protected from paralysis. ASID impla nts were rich with autoimmune cells, however, reactivity to cognate antigen was substantia lly diminished and apoptosis was prevalent. ASID-implanted mice consistently exhibited engorged spleens when disease normally peaked. In addition, splenocyte antigen-presenting cells were highly activated in response to PLP rechallenge, but CD3+ and CD19+ effector subsets were significantly decreased, suggesting exhaustion. ASID-implanted mice never developed EAE relapse symptoms even though the ASID material had long since degraded, suggesting exhausted autoimmune cells did not recover functionality. Together, data suggested ASIDs were able to sequester and exhaust immune cells in an antigen-specific fashion, thus offering a compelling approach to inhibit the migration circuit underlying autoimmunity.
an appealing improvement to the state of conventional treatments, promising to selectively disarm autoreactive cells while preserving healthy immune function.
Conventional migration-inhibiting immunotherapies broadly block cellular egress from lymph nodes [19] or extravasation across the blood brain barrier [20] . Conversely, an antigenspecific approach may necessitate selectively attracting autoimmune cells or autoantibodies to a surrogate locale for sequestration. Engineered implantable biomaterials have emerged for evoking therapeutic, antigen-specific immune responses against cancer and autoimmunity alike [24] [25] [26] [27] [28] [29] [30] .
These materials create a unique niche [31] [32] [33] [34] [35] [36] of antigen to recruit and tune antigen-presenting populations for activation or tolerance, often by including a stimulatory adjuvant or immunosuppressive drug [37] [38] [39] [40] [41] [42] [43] [44] [45] .
We designed and tested a novel biomaterial, which mimics etiologic autoantigens via covalent surface conjugation of a peptide epitope to microporous collagen sponges. Antige n-Specific Immune Decoys (ASIDs) were designed to short-circuit the SLO-host tissue circuit by sequestering autoreactive effector cells from circulation, ultimately preserving host organs. Using murine experimental autoimmune encephalomyelitis (EAE) as a model, we set forth to evaluate the prophylactic, subcutaneous implantation of ASIDs for preventing paralysis in vivo. Analyzing cell isolates from both sponges and spleens, we explored the hypothesis that these constructs could work by intercepting T cell proliferation in the periphery. Ultimately, we discovered that ASIDs overstimulated immunity and exploited antigen-specific exhaustion as a mechanism for therapeutic effect (Fig. 1) . Figure 1 . Autoimmunity is primed in secondary lymphoid organs and travels to disease-implicated tissues. ASIDs were designed to intercept this response and exhaust it prematurely, leaving host tissue intact.
RESULTS

Synthesis and Functional Characterization of ASIDs.
We designed ASIDs as an implantab le depot displaying covalently-coupled autoantigen. Microporous collagen sponges were selected as a scaffolding material due to immunologically inert nature and widespread clinical utility since the 1970s [46] . We hypothesized primary amine moieties would be chemically accessible on the surface of these collagenous materials ( Fig. 2a ) and pore diameters of ~200 µm would facilitate unhindered cell infiltration and nutrient transfer (Fig. 2b) . To qualitatively assess surface accessibility of primary amines, a bifunctional NHS-PEG4-Azide linker was installed to collagen sponges, and rhodamine-alkyne was successfully conjugated using copper (I)-catalyzed azidealkyne cycloaddition (Fig. 2c) . Likewise using the same chemistry, a homopropargyl version of model autoantigen PLP139-151 (hpPLP) was coupled to the collagen sponges to synthesize ASIDs.
PLP conjugation was confirmed via RP-HPLC.
The functionality of conjugated autoantigen was then validated. ASID and Blank collagen sponges were each incubated in anti-PLP IgG-positive mouse serum. HRP-conjugated anti-mouse IgG was used to detect bound autoantibody (Fig. 2d) , and the ASID, but not Blank sponge, showed successful capture. Additionally, EAE splenocytes were harvested at peak of disease and cultured ex vivo with ASIDs. Functional outcomes were compared with cells stimulated with 25 µM soluble PLP139-151 as well as vehicle control ( Fig. 2e-g) . After 96 hours, splenocytes cultured with ASID exhibited a significantly elevated metabolism over vehicle control ( Fig. 2e) , and CD86 expression levels were analogous to cells stimulated with soluble antigen (Fig. 2f) . Likewise, soluble PLP and ASIDs generated robust IL-17 secretion, though only ASID culturing enabled high IL-12 after the incubation, indicating sustained APC activity ( Fig. 2g) .
Figure 2. Synthesis and characterization of immunologically active PLP-conjugated ASIDs. a)
The synthesis reaction scheme modified surface primary amines on collagen sponges with an azide-functional PEG linker subsequently clicked to homopropargyl PLP139-151. b) Microporous collagen sponges were used with an average pore size of approximately 200 µm. c) To visualize surface accessibility of primary amine moieties, rhodamine-alkyne was installed (left) and imaged compared to a Blank sponge (right), where dye conjugation could be confirmed. d) ASID with surface-conjugated PLP (left) captured anti-PLP IgG (note blue color) from mouse serum and a Blank collagen sponge (right) did not. e) Day 12 EAE Splenocyte metabolism was measured after incubation with vehicle (-PLP), soluble antigen (+PLP), or ASID. ASIDs significantly elevated metabolism over vehicle-treated splenocytes after 96 hours. f) Under the same conditions, CD86 expression was measured by flow cytometry, where ASIDs likewise upregulated costimulation in a manner similar to that of soluble antigen. g) In the same experiment, quantification of cytokine production showed that inflammatory IL-17 (left) was elevated by both +PLP and ASID treatment, however APC-indicating IL-12 (right) was only stimulated by incubation with ASIDs. (Statistical analysis was performed against -PLP as a control. n = 3/group, *p < 0.05, **p < 0.01, ***p < 0.001).
Subcutaneous Implantation of ASIDs prevents EAE in vivo.
To investigate ASID therapeutic capacity, we subcutaneously implanted EAE mice with these constructs between the shoulder blades on day 7 post-induction, prior to the onset of symptoms ( Fig. 3a) . Healthy mice were also implanted with ASID to assess whether decoys themselves would stimulate an immune response.
All implanted sponge constructs were sterilized and soaked overnight in a solution of 1200 ng/mL mouse GM-CSF prior to implantation to create impetus for cell infiltration and to normalize for inflammatory discrepancies that may have arisen from variability in surgery. ASIDs highly suppressed EAE in vivo, both in terms of significant scoring reduction as well as weight loss ( Fig.   3b-d) . Only two of four ASID mice showed any EAE symptoms at all, and none exhibited substantial paralysis which is defined as a clinical score of 2 or greater ( Fig. 3e) . Blank sponge implantation and Mock Surgery had no significant clinical effect on disease course, as these mice did not vary as compared to EAE alone with no surgical procedure or treatment. Control disease in this study was severe, as one mouse from the Blank group and one mouse from the Mock Surgery group each succumbed to disease at its peak. Strikingly, weight gain in EAE mice treated with ASID mirrored that of the healthy mice that were completely unhindered by disease ( Fig. 3c) .
At the conclusion of the study, serum and whole brain homogenates were collected. Anti-PLP139-151 IgG ELISA was used as previously described [47] [48] [49] to detect relative autoantibody titers between the periphery (serum) and CNS (homogenized whole brain, Fig. 3f, Supp. Fig. 1 ).
EAE mice implanted with an ASID presented with an elevated serum anti-PLP titer that did not translate to significant increases in CNS autoantibody. 
ASID Infiltrates undergo Apoptosis upon PLP Rechallenge.
We hypothesized the persistent, antigen-specific depot in ASIDs could selectively sequester autoreactive cell populations responsible for propagating autoimmunity to prevent disease. To evaluate this proposed decoy mechanism, we implanted EAE mice with both a Blank collagen sponge as well as an ASID on day 7 post-induction ( Fig. 4a ). Sponges and spleens were harvested at typical disease onset (day 10) or peak of disease (day 14). Cells were isolated and rechallenged with 25 µM PLP for 96 hours. At day 10, there were no significant differences in resazurin cell metabolism across splenocytes and sponge isolates ( Fig. 4b) , though ASIDs were considerably more degraded than Blank sponges ( Fig. 4c) . At day 14, metabolism in ASID infiltrates was roughly halved as compared to the Blank sponge and spleen (Fig. 4b) . These results were initially surprising as we expected PLP-specific cells isolated from ASIDs to elicit a greater metabolic response upon rechallenge. To further investigate, harvested sponges were cryosectioned and Masson's trichrome staining was used to assess morphological differences ( Fig. 4c) . Reflecting resazurin metabolism data, few differe nces were observable at day 10 (though ASID sections showed relatively more cell infiltrates). In contrast, ASID infiltrates appeared disjointed and unhealthy at the day 14 timepoint, while Blank sponge sections showed apparently healthy, ordered cell structures. Bright field microscopy of isolated splenocytes and spongeocytes after 96-hour PLP rechallenge corroborated apoptotic allusions. ASID isolates at the day 14 timepoint were clearly dying off in comparison to the Blank isolates and splenocytes. 
ASIDs Return Exhausted Immune Cells to Secondary Lymphoid Organs.
In the same-anima l implant experiment ( Fig. 4) , we noticed that secondary lymphoid organs appeared substantia lly engorged at times in disease course when splenopenia is typical, due to autoimmune cell egress to the CNS (Supp. Fig. 2 ). To further probe this phenomenon as a potential mechanistic underpinning of ASID efficacy, we implanted EAE mice with either an ASID, Blank sponge, or Mock Surgery on day 7 post-induction and harvested at peak of disease on day 14 (Fig. 5a) . ASID-impla nted mouse spleens were larger than those of the other groups by a factor of 4, and a similar size discrepancy in lymph nodes was evident ( Fig. 5b, Supp. Fig. 3 ). The largest numbers of splenocytes were also harvested from these spleens, where yields averaged a multiple of two and four times those from Mock and Blank controls, respectively. Cells were also isolated from sponges, and ASID isolates numbered roughly 5 million cells per construct while Blank infiltr ates were on the order of 10,000 cells per sponge ( Fig. 5b) .
Isolated splenocytes and spongeocytes were rechallenged with media alone, 25 µM PLP, or 2.5 µg/mL of mitogenic Concanavalin A (ConA) for 96 hours (Fig. 5c ). Unchallenged ASID splenocytes showed a significantly higher level of metabolism after the incubation (compared to controls), but the inclusion of PLP or ConA abrogated this increase. In the sponges, ASID isolates exhibited metabolism that was not exhaustive in response to PLP or ConA, and was significa ntly elevated over Blank sponge isolates, but these cells were much lower in number as mentioned above (Fig. 5b) .
Flow cytometry was used to phenotype splenocytes immediately after harvest ( Fig. 5d, e ).
Moving from our previous same-animal experiment and observations of enlarged spleens, we hypothesized that ASIDs may have worked to evoke antigen overstimulation to exhaust the EAE autoimmune response and prematurely return perpetrating cells to secondary lympho id organs. In accordance with our hypothesis, we found T (CD3+) and B (CD19+) cell populations to be significantly depleted in ASID spleens compared to those of Mock Surgery (Fig. 5d ). Seemingly conflicting with these decreased levels of effector subsets, though, was an increase in CD11c+ APCs ( Fig. 5d ) and comparable levels of CD86+CD80+ costimulatory expression ( Fig. 5e ). 
Antigen-Specific Exhaustion Persists after PLP rechallenge. Moving from baseline
phenotyping, day 14 splenocytes were also rechallenged with 25 µM PLP for 96 hours. After the incubation, many baseline trends persisted ( Fig. 6a) . ASID splenocyte CD3+ T cells remained lower in proportion to controls both with and without rechallenge, though CD19+ B cells were relatively similar at this time point. CD11c+ APCs were significantly elevated when incubated with vehicle media, but not significantly different when challenged with antigen. However, an inverted antigen rechallenge trend was appreciable; the inclusion of PLP led to expanded CD11c+ populations in Mock and Blank controls, but led to a decrease when included with ASID splenocytes (Fig. 6a) . Despite this decrease, the CD11c+ proportion of rechallenged ASID splenocytes was slightly higher than those of the controls. Costimulation was promoted upon rechallenge without exception across groups, but PLP rechallenge in ASID splenocytes promoted exorbitantly higher levels of CD80+ as well as CD86+CD80+ double positive cells (Fig. 6a) .
One major limitation of the EAE model is a lack of tools for probing antigen-specific ity.
In recent years, our group has published a multivalent nanomaterial known as the soluble antigen array (SAgA), which has been developed as an antigen-specific immunotherapy [50] [51] [52] [53] . SAgAs evoke efficacy by specifically engaging surface-bound B cell receptors [54] [55] [56] [57] . In this study, we hypothesized that fluorescently labeled SAgAs could identify antigen-specific B cells much in the same way that MHC-tetramers are employed for T cells. By including SAgAs with other fluorescent antibodies, we developed a method in which antigen-specific cells could be identified by gating on CD19 (Fig. 6b, Supp. Fig 4) . Extrapolating this protocol allowed identification of antigen-specific subsets of B cells in EAE splenocytes (Fig. 6c) . CD19+CD11c+ autoimmuneassociated B cells (ABCs) have been reported as potent, antigen-specific instigators of immunity in EAE and autoimmune disease alike [57] [58] [59] . Interestingly, ASID splenocytes showed significantly elevated proportions of this population when incubated with vehicle ( Fig. 6c) , though much like resazurin (Fig. 4b, Fig. 5c ), these cells were diminished by PLP rechallenge. The SAgA probe verified this trend was conserved within the antigen-specific CD19+CD11c+ ABC subset, but not the broader CD19+ B cell population. 
Pro-inflammatory Cytokines are Elevated in ASID-Treated Splenocytes at Day 14 and 25.
In addition to phenotypic changes in response to antigen rechallenge, we assessed cytokine responses in splenocytes harvested on day 14 or 25 and cultured with 25 µM PLP or vehicle for 96 hours (+PLP reported in Fig. 7a , -PLP and absolute concentrations in Supp. Fig. 7) . At day 14, ASID mice showed increased in pro-inflammatory cytokines GM-CSF, IFN-γ, and IL-6 as compared to the Mock Surgery group, while splenocytes from mice implanted with a Blank sponge largely secreted less of each analyte screened. At day 25, ASID-treated splenocytes still exhibited elevated levels of pro-inflammatory cytokines IFN-γ, IL-15, IL-17, and IL-6, though at this point, antiinflammatory IL-10 was most profoundly upregulated.
We contextualized cytokine trends across a number of mechanistically indicative ratios ( Fig. 7b) . IL-2/IL-17 was used as a measure of T cell proliferation proportional to overall EAE inflammation. Mock Surgery and Blank-treated mice showed increases in T cell proliferation at day 14 which was resolved by day 25, but ASID treatment appears to have restricted IL-2 at peak of disease. This trend is in concordance the exhaustive mechanism suggested by our other experiments. IL-12/IL-2 was used to interrogate the balance between APCs and T cells. Consistent with our earlier observations, ASID-treatment seems to cause an upward skew in this ratio, where APC levels are sustained while IL-2 is diminished. Finally, to investigate the observed increase of IL-10 from ASID splenocytes at day 25, IL-10/IFN-γ was employed to probe a potential tolerogenesis where anti-inflammatory IL-10 precludes pro-inflammatory IFN-γ production.
Interestingly, despite these observed increases in IL-10, IFN-γ remains proportionally abundant such that this ratio fell well within the bounds of the controls.
Finally, we sought to discern whether ASID implantation would protect mice from the recurring paralysis that is characteristic of the PLP139-151-EAE model. In our early studies, ASIDs and Blank sponges alike were found to be completely resorbed by day 25. We wondered if a durable therapeutic effect could be realized as a result of ASID-induced cell exhaustion (Fig. 7c) .
During the initial phase of disease, only one of three ASID recipients displayed any EAE symptoms, and each of the Mock Surgery cohort exhibited a fully severe initial presentation.
Remarkably, all ASID-implanted mice were protected from recurrent disease through day 60 while two of three Mock Surgery mice displayed robust relapses on days 37 and 38 post-induction. Ex vivo analyses revealed few differences between splenocytes in response to PLP rechallenge (Supp. 
DISCUSSION
Previous works exploring antigen-specific immunotherapies for autoimmunity delivered autoantigen in vastly differing ways, including soluble, insoluble, and biomaterial compositio ns.
ASIDs utilize covalent attachment of autoantigen onto a microporous scaffold to inhibit EAE in vivo when implanted subcutaneously after disease induction, but before the appearance of symptoms. Past work exploring immunologically-active therapeutic biomaterials has mostly explored co-delivery formulations [27] . To our knowledge, ASIDs represent a first demonstratio n of antigen-specific immune cell sequestration for therapeutic effect. Recently, the Serwold group disseminated an implantable biomaterial soaked in autoantigen for the purpose of homing and enriching antigen-specific populations in models of Type 1 Diabetes, but interestingly, no therapeutic effect was realized [35] . Our data also indicated antigen-specific cell infiltration into ASIDs (Fig. 4, Fig. 5b) , but the therapeutic capacity we observed likely resulted from the specification of irreversible epitope conjugation to our constructs, which has been well described to enable antigen persistence and boost T cell stimulation [60] . In our example, such overstimulation proved itself a driver of effect through exhaustion and may explain our differentia l therapeutic success.
ASIDs elicited robust DC activation ex vivo (Fig. 1e-g) . We initially hypothesized that this mechanism would solely facilitate the recruitment and sequestration of T and B effectors in vivo.
When implanted, however, ASIDs spurred exhaustion and apoptosis within the constructs (Fig.   3 ). Evidence has emerged regarding the potential for "therapeutic exhaustion" by extrapolating a liability observed during chronic infection for possible benefit in autoimmunity [61] . In our studies, exhaustion was implicated in the prevention of disease. Spleen weights correlated highly with suppression of EAE, where engorgement was likely a consequence of ASID-induced exhaustion and return to SLOs (Fig. 5b, Supp. Fig. 3 [14, 62] . The exhausted state of splenocytes in ASID-treated mice was corroborated by effector non-responsiveness to antigen rechallenge.
Despite the presence of CD86+CD80+ active DCs (Fig. 5d, e, and Fig. 6) , we observed an absence of IL-2 despite upregulation of other inflammatory markers such as IFN-γ ( Fig. 7a, b) .
Interestingly, proliferation of resting (unchallenged) ABCs was diminished in the presence of PLP rechallenge (Fig. 7c) . Abrogated proliferation was most severe in the antigen-specific population of this subset, suggesting that population changes may be driven by PLP-specific mechanis ms.
Autoimmunity was restricted to the periphery, exclusive of the CNS, as evident in the elevation of serum anti-PLP IgG, which was not observed in homogenized brain (Fig. 3f) . In effect, the PLP-specific response was short-circuited and exhausted in ASID-treated mice, which translated to therapeutic success.
Remarkably, no ASID-implanted EAE mice developed significant disease (score >1) over 60 days. All three Mock Surgery-receiving counterparts exhibited severe primary EAE, and two of these mice exhibited robust flare-ups over this interval after day 25 (Fig. 7c) . After the initia l 25-day efficacy study, ASID and Blank constructs had been completely degraded, so this experiment was conducted to observe relapsed autoimmunity that is typical of the PLP139-151-EAE model. We originally expected ASID-treated mice to develop paralysis similarly to those given Mock Surgery by virtue of regained functionality after exhaustion, perhaps even at a higher rate or intensity of disease due to a delayed hypersensitivity reaction. In retrospect, initial disease prevention in ASID mice may have limited primary tissue inflammation and abrogated subsequent migration to the CNS.
Alternatively, ASID implantation could have induced differentially robust exhaustio n similar to what is observed in chronic infection where clonal deletion or permanent anergy can ensue [18, [63] [64] [65] . In the EAE model employed here, immunity is generated against the PLP139-151 epitope, a small fraction of the larger PLP antigen, which is ultimately one of many constitutive building blocks of the myelin sheath. As a result, PLP139-151 density in the CNS is low and inaccessible relative to an ASID [66] . Conversely, PLP139-151 density in ASIDs is high and by design, easily accessible to extravasating immune cells. Antigen density is known to highly dictate costimulation and downstream immunity [66] [67] [68] [69] , where excessively high density can drive overstimulation and cell death [70] [71] [72] . Differences in these outcomes were evident between ASID-implanted mice and controls, especially in histological studies and bioassays of spongeocytes (Fig. 4) .
In clinical practice, some of the most effective MS therapeutics such as natalizumab and fingolimod work by inhibiting immune cell migration and trafficking to the CNS [19, 20] . Such drugs have a steep trade-off, risking life-threatening consequences of nonspecific immunosuppression for therapeutic efficacy [21] [22] [23] . By demonstrating the potential to affect immune cell migration in an antigen-specific fashion, our work suggests autoimmunity may be short-circuited in potent, yet safer ways. Additional studies will determine if ASID performance can be extrapolated to a broader palette of autoantigens and if therapeutic efficacy can be achieved when intervening at different points in the disease. The immunological mechanism of ASID capture, deactivation, and release of exhausted autoimmune cells offers a new paradigm to short circuit immune cell migration to prevent relapsing autoimmune diseases. Induction of EAE and Therapeutic Study. EAE was induced as previously described [47, 59] Detection of Anti-PLP IgG. PLP-specific IgG titers were assessed in an ELISA format as previously described [47, 48] . Briefly, 1µg/mL PLP was dissolved in a pH 9. 
METHODS
Materials
Spleen Harvest and Splenocyte Isolation. Spleen harvest and splenocyte isolation was conducted
as previously reported [57] . Briefly, spleens were passed through a wire mesh using the rubber stopper of a sterile 1 mL syringe in 1X PBS. The strained cellular extracts were centrifuged, and the cell pellet was resuspended in red blood cell lysis buffer. The cells were incubated on ice for 3.5 minutes to lyse splenic red blood cells. The lysis reaction was stopped by adding 10 mL RPMI 1640 media containing 10% FBS to the mixture before centrifuging. The remaining splenocyte pellets were resuspended in fresh media (RPMI 1640 media containing 10% FBS and 1% Penicillin-Streptomycin) and counted for further analysis and experimentation.
Sponge Harvest and Spongeocyte Isolation. Cellular infiltrates to ASIDs and Blank Sponges were
isolated by retrieving sponges from the subcutaneous space. In an Eppendorf tube, sponges were either chemically digested using 0.5 mg/mL Liberase TL (Sigma Aldrich, St. Louis, MO) in HBSS or mechanically disrupted with microscissors. The resulting freed cell suspension was then passed through a 70 µm strainer. The suspension was pelleted, replenished with 1 mL of RPMI 1640 media containing 10% FBS and 1% Penicillin-Streptomycin, and cells were counted for further processing and plating.
Fluorescent Staining and Flow Cytometry
Splenocytes were collected from 24-well plates after 96 hours and stained with fluorescent antibodies according to manufacturer recommendatio ns.
Cells were washed with 1X PBS + 5% FBS + 0.1% sodium azide before being incubated for 20 minutes with Zombie Aqua viability stain (Biolegend) at room temperature. Following the incubation, fluorescent antibodies and isotype controls were added for 30 minutes on ice. For flow cytometry data collection, 100,000 cells per sample were targeted using a BD FACSFusion cytometer. Data were analyzed using FlowJo and GraphPad Prism software.
Measurement of Cellular Metabolism. 75 µM Resazurin (7-hydroxy-3H-phenoxazin-3-one 10oxide) was incubated with splenocytes in a 96 well plate for 3 hours. Metabolic reductive capacity was observed by viewing changes in fluorescence at excitation 560, emission 590 (Spectramax M5, Molecular Devices). Background fluorescence was taken using RPMI media and subtracted out from splenocyte readings for analysis.
Measurement of Cytokines
Following a 96-hour incubation, splenocytes in a 96-well culture plate were centrifuged. Supernatants were collected for cytokine analysis (GM-CSF, IFN-γ, IL-2, IL-21, IL-6, IL-10, IL-17, IL-23, TNF-α). Marker levels were detected using a U-Plex assay kit according to manufacturer instructions (Meso Scale Discovery). Each assay plate was read using the QuickPlex multiplex plate reader (Meso Scale Discovery).
Histology. Resected sponges and tissues were cryoembedded with Tissue-Plus O.C.T. Compound (FisherSci) and sectioned into 20 µm on microscope slides in triplicate. Slides were fixed in 10% neutral buffered formalin for 10 minutes, and Masson's trichrome stain (Sigma Aldrich) was conducted.
Statistical Analysis Statistical evaluation was performed using one-way analysis of variance (ANOVA), followed by Tukey and Sidak multiple comparison tests. Statistical significance for all analyses was set at p<0.05. All statistical analyses were performed using GraphPad Software (GraphPad Software Inc.).
